SPECIAL THANKS PROGRAM

AWARDS MANUFACTURING Welcome Bob Buderi, Xconomy

X of the Year Award

Emcee Introductions Susan Windham-Bannister, Biomedical Growth Strategies AWARDS DESIGN Rob Perez, Life Science Cares Big Idea Award

Newcomer Award

Lifetime Achievement Award • George Whitesides presented by Ramita Tandon, ICON

Contrarian Award

GALA CENTERPIECES Young Innovator Award A Tribute to Henri Termeer presented by Alison Lawton, Aura Biosciences

Patient Partnership Award

Startup Award

3D MODELS (USED IN STARTUP TROPHY) CEO Award

Lifetime Achievement Award • Lita Nelsen Little rocket by KAD370 presented by Ramita Tandon, ICON Published on October 29, 2016 www.thingiverse.com/thing:1857704 Commitment to Diversity Award

Creative Commons - Attribution Innovation at the Intersection Award presented by Christopher Otey, Alexandria Real Estate Equities

Closing Remarks Flame Game Pieces by BrayChristopher Bob Buderi Published on June 23, 2017 www.thingiverse.com/thing:2399951 Creative Commons - Attribution DINNER MENU New England Spinach & Apple Salad Rosemary Chicken Breast Little Black Dress Pinot Grigio or Gascon Mendoza Malbec Tiramisu Please notify your server if you requested a vegetarian or gluten free meal. FINALISTS FINALISTS

Perez is LSC’s chairman and was a long-time executive at Cubist Pharmaceuticals X of the Year before Merck bought it in 2015.

NOUBAR AFEYAN — DEALMAKER OF THE YEAR ANNA PROTOPAPAS — CLOSER OF THE YEAR Noubar Afeyan founded Flagship Ventures in 2000 (renamed Anna Protopapas spearheaded many deals at Millennium Pharmaceuticals, in- in 2016) and has grown it to become one of the leading venture capital firms in cluding the company’s biggest deal of all, its $8.8 billion buyout by Takeda in 2008. the Boston area. Afeyan and his firm are known to make big bets in risky fields of She went on to oversee business development for the entire company, and led science. Flagship incubated both the messenger RNA drug developer Takeda’s 2011, $12 billion acquisition of Switzerland-based Nycomed. Two years Therapeutics, now reportedly worth more than $5 billion, and Seres Therapeutics, later, she was named Millennium’s president, replacing Dunsire. In 2015, Protopa- the first microbiome company to go public in the U.S. pas became president and CEO of Mersana Therapeutics. In her two years at the helm, Mersana raised a $33 million Series C, started its first clinical trial, and closed DEBORAH DISANZO — TECH/HEALTHCARE CONNECTOR OF THE YEAR a $75 million IPO. IBM formed its Watson Health business in 2015 to bring its “cognitive computing” technologies to healthcare. It hired Deborah DiSanzo—former CEO of Philips VICKI SATO — XPORT OF THE YEAR Healthcare—to be Watson Health’s general manager. IBM has since spent more After a long career in various leadership positions across the Boston biotech scene, than $4 billion acquiring healthcare-computing companies. DiSanzo has led her Vicki Sato is making another career switch, this time as a Boston life science export 7,000-employee group in forming partnerships with a myriad of organizations in to New York (she splits her time between the two cities). Sato co-chairs an advisory healthcare and life sciences to get access to the health-related data and exper- committee for LifeSci NYC, a 10-year, $500 million government-funded plan to grow tise needed to make IBM’s technologies smarter. the life sciences industry in New York City. The initiative has so far helped launch a biotech incubator at the NYU Langone Medical Center, but LifeSci NYC, with Sato’s DEBORAH DUNSIRE — ADVENTURER OF THE YEAR help, has much more planned to help boost the city’s biotech ambitions. Deborah Dunsire spent nearly 20 years of her career at large public compa- nies, eight of those years as CEO and president of Millennium Pharmaceuticals, which is now a unit of Takeda. Since then she’s embarked on a few far differ- Big Idea ent adventures. First, in 2013, she took the helm of Forum Pharmaceuticals, an unusual, privately held neuroscience company that she tried to steer through ARRAKIS THERAPEUTICS wants to use small molecule drugs to block RNAs, shifty large, ambitious, and ultimately unsuccessful late-stage clinical trials. Now molecules that were long thought to be undruggable. The hope is this can lead she’s leading a small, two-year-old startup that is at least a year away from to therapies that target RNAs that may drive cancer, neurological disease, and human studies. certain rare genetic disorders. Arrakis closed a $38 million Series A in February and named biotech veteran Michael Gilman as its chairman and CEO. KENNETH KAITIN — THOUGHT LEADER OF THE YEAR Kenneth Kaitin has led the Tufts Center for the Study of Drug Development since the THE BRIDGE PROJECT was hatched by MIT’s Koch Institute for Integrative Cancer 1980s. The group has generated some of the most often-cited data about the high Research in Cambridge and the Dana-Farber/Harvard Cancer Center in Boston cost of developing new drugs, and also produces many reports on R&D trends, ef- to encourage more collaboration between cancer researchers from MIT and Har- ficiency, and regulation. vard-affiliated hospitals and schools. Their aim is to tackle cancers that have been tough to treat, such as pancreatic and brain cancer, and to move new treatment ROB PEREZ — COMMUNITY CONTRIBUTION OF THE YEAR strategies into the clinic. Rob Perez founded the nonprofit Life Science Cares (LSC) in 2016. LSC raises money from companies and individuals in the life sciences community and donates it ANDREW LO is an MIT Sloan School of Management professor and the director of to nonprofits that the firm has vetted and partnered with for their work in fighting MIT’s Laboratory for Financial Engineering. He is known for proposing big, unusual poverty in Boston. LSC also connects volunteers from industry with these partners. ideas on how to make drugs more affordable and how to better manage the FINALISTS FINALISTS

risks of drug development through alternative financing models. Some companies & TECH HUB operates like a mini-biotech within LEO, striking research deals with have implemented Lo’s proposals, and he has founded an investment research universities and startups. and management firm that runs funds based on his theories of risk perception. veteran AMY SCHULMAN has big pharma experience, but in Boston she dis- READCOOR’s technology allows RNA to be sequenced inside individual cells and covered her startup side. In 2014, she moved to Boston and joined Polaris Partners tissues so that researchers can pinpoint the location and identity of many RNA mol- as a venture partner and became CEO of Arsia Therapeutics. Arsia was acquired ecules at a time without having to destroy cells or tissues. The technology—fluo- in 2016, and Schulman is now CEO of drug-delivery startup Lyndra. She also teach- rescent in situ sequencing—could provide new insight into which genes are being es leadership and corporate accountability at . turned on and where, and have applications in neuroscience and cancer biology.

THE SYNC PROJECT is developing music as precision medicine. The startup is a col- Contrarian laboration between the company creator PureTech Health and scientists and musicians to study how music affects the body, and use those insights to design As CEO of Sarepta Therapeutics from 2011 to 2015, CHRIS GARABEDIAN was in- music-based therapeutics. The group aims to test, in clinical trials, whether these strumental in helping push the first approved Duchenne muscular dystrophy drug interventions can improve sleep and reduce stress and pain. through clinical development. He also adopted a controversial and contrarian strategy to get the FDA to review the drug with only a small amount of data. Now Garabedian runs an accelerator called Xontogeny that partners with entrepre- Newcomer neurs to help turn nascent life science technologies into biotech startups.

Cambridge, U.K.-based BICYCLE THERAPEUTICS moved to Boston in 2016 to take TILLMAN GERNGROSS is the CEO and co-founder of antibody discovery firm Ad- advantage of the region’s deep talent pool and launch its cancer business here. imab, which does not fit the usual profile in biotech: it is self-sustaining, profitable, Since then, the company has made some key hires in oncology and added new and privately held. That unusual path, combined with the in-your-face gusto U.S.-based investors. Its technology is based on peptides that can deliver drug Gerngross has become known for, has helped earn the outspoken Gerngross— payloads and also be directed to specific molecular targets. a biochemical engineer by training, a Dartmouth professor, and a serial biotech entrepreneur—a spot on our list of contrarian finalists. BLUE EARTH DIAGNOSTICS established its Boston-area presence in 2015 as the U.K.- based company was planning its regulatory and commercial efforts for the U.S. STEVEN PEARSON is the founder and president of the nonprofit Institute for Clinical market. FDA approval of Blue Earth’s cancer-imaging agent came shortly after and Economic Review (ICER). The group uses complex calculations to recalibrate the company’s arrival in . The region’s talent base and advanced the drug industry’s stated value of its products, often putting a price on drugs that healthcare industry allowed Blue Earth to move quickly in hiring and bringing its is far lower than what companies charge. The industry has criticized ICER’s meth- product to the market. ods, but the group’s reports have helped move the needle on the debate over the high cost of drugs. Last year, CENTREXION THERAPEUTICS was eyeing late-stage clinical trials for its lead drug, a non-opioid painkiller, as well as tests for three more pain drug candi- dates the company had added to its pipeline through acquisition. The Baltimore Young Innovator company decided to relocate to Boston to access the expertise it would need to move through phase 3 trials, which the firm plans to start by the end of this year. As an MIT grad student, FEI CHEN invented a microscopy technique that has given researchers studying cells a four to fivefold boost in resolution without requiring them Denmark-based LEO Pharma has a 100-year history developing skin disease drugs. to buy expensive new equipment. Called expansion microscopy, the method uses But when it was looking for places to find new technologies to improve the diagno- gels to expand cells and tissues from within so that cell components can be better sis and treatment of skin conditions, the company chose Boston. The LEO SCIENCE distinguished. Chen, 27, now leads a small research group at the Broad Institute. FINALISTS FINALISTS

CRAIG RUSSO, 24, is the co-founder and CEO of LabMate. The website, which went ance to conduct a survey of patients and doctors, and then created a website to live in May, allows academic scientists to post profiles offering their services as share the survey results. From it, users can download that information along with consultants to drug developers and investors. These firms can also post short-term a discussion guide intended to help patients ask their doctors the right questions projects and LabMate aims to match the companies with the scientists, which, ide- about their treatment. ally, would help them land full-time industry jobs. NIKHIL WAGLE, a breast cancer oncologist and researcher at the Dana-Farber While at MIT, ARMON SHAREI developed a relatively simple method to disrupt cell Cancer Institute and Broad Institute, wanted to understand why some people with membranes enough to allow large molecules like proteins to quickly slip inside metastatic breast cancer respond better to drugs than others, and why some have cells. Sharei, now 30, co-founded SQZ Biotech to sell the cell-squeezing tool to more aggressive disease. He worked with patients to create the Metastatic Breast academic researchers. He joined the company as CEO in 2015 when it switched its Cancer Project, which collects and sequences DNA from patients’ tumors and focus to developing cell therapies for cancer and other diseases. looks for genetic changes that are associated with how those patients responded, or didn’t respond, to treatment. As part of his PhD at MIT, ANDREW WARREN took newly developed technol- ogy for a urine-based diagnostic and made it simpler and more reliable and adapted it for use in diagnosing and monitoring a liver disease called non-al- Startup coholic steatohepatitis. After finishing his graduate work in early 2016, Warren, now 28, joined a startup, Glympse Bio, as the founding scientist to commercial- DRAGONFLY THERAPEUTICS is a cancer immunotherapy startup created out of the ize the test. labs of MIT cancer research pioneer Tyler Jacks and David Raulet, a UC Berkeley immunologist, and is funded not by venture firms, but by a small, unusual group of family offices. Dragonfly aims to harness natural killer cells, a key member of the in- Patient Partnership nate immune system (the body’s first line of defense), to fight cancer, and already has a wide-ranging alliance with . FULCRUM THERAPEUTICS reached out to patient groups even before the company was officially formed in 2016. Those early conversations led the company to focus To address the donor organ shortage, EGENESIS wants to engineer pigs to grow from the beginning on developing drugs for Fragile X syndrome and facioscapu- organs and tissues that can be transplanted into humans. To make this safer, the lohumeral (FSH) muscular dystrophy. Fulcrum has since deepened ties with groups company is using CRISPR-Cas9 gene editing technology to inactivate viruses, representing these patients. The FSH Society, for instance, is helping the company called PERVs, in pigs. eGenesis scientists recently showed that they could clone obtain muscle tissue samples from people with the disease—something Fulcrum pigs that do not have the viruses. The company also raised a $38 million Series A will use to try to develop drugs. round earlier this year.

SHIRE has partnered with PatientsLikeMe to create online communities for people HOMOLOGY MEDICINES wants to one-up CRISPR-Cas9 drug developers with a affected by two conditions that the rare disease drugmaker has approved or ex- different gene-editing method that, it believes, might be safer than other strate- perimental treatments for: Hunter syndrome, and complications from being born gies. The company is developing newer, different versions of viruses called AAVs extremely premature. PatientsLikeMe has worked with several other drugmakers that are designed to edit DNA using homologous recombination—a natural DNA and runs a website where patients can create profiles, connect with one another, repair mechanism in cells. It has raised a total of $127 million in financing since and share their health information. Shire paid PatientsLikeMe to build the plat- launching in 2016, including an $83.5 million Series B round last month. forms, and the plan is for them to launch this fall. Through a series of acquisitions and other deals, SPERO THERAPEUTICS is building TESARO realized from discussions with patient groups how little those with ovar- an armamentarium of weapons to kill drug-resistant bacteria. One, for instance, ian cancer knew about what to expect after diagnosis. So it teamed up with the doesn’t destroy bacteria on its own, but instead disrupts the outer membrane of National Ovarian Cancer Coalition and the Ovarian Cancer Research Fund Alli- tough-to-drug Gram-negative bacteria so that they’re susceptible to antibiotics. FINALISTS FINALISTS

Spero just raised $51.7 million this year, and $110 million in total since its 2014 incep- Seven years after LONNIE MOULDER signed on as Tesaro’s CEO, the company is tion. After that last raise, CEO Ankit Mahadevia mentioned Spero might seek an publicly traded and has two approved drugs and a market capitalization of $7 IPO in the future. billion. In March, one of those drugs, niraparib (Zejula), became the first ever main- tenance therapy approved for ovarian cancer. Tesaro’s shares are now trading VERITAS GENETICS last year became the first company to offer whole genome nearly nine times their IPO price in 2012, and have more than doubled in value sequencing, interpretation, and genetic counseling for less than $1,000—a price since May 2016. point that some say will make the service more accessible to consumers. It also recently acquired Curoverse, the bioinformatics company behind Harvard’s Per- PAULA RAGAN led the partnering efforts for ’s big rare disease business. sonal Genome Project, as part of a plan to use machine learning to scale up and She left in 2012, but cut a deal with her former employer to grab rights to a shelved analyze hundreds of thousands to millions of genomes. drug program she thought might be useful for cancer immunotherapy. Two years later, that deal became the foundation of her own company, X4 Pharmaceuti- ZAPPRX runs a website and mobile app that makes the complex process of filling cals. Ragan raised a $37.5 million Series A round in late 2015, and X4 now has a prescriptions for specialty medicines faster and more efficient. Founder and CEO pipeline of drug candidates, three of which are in clinical testing for cancer and Zoe Barry has raised about $41 million in venture funding since 2012, and the com- rare diseases. pany’s technology is now being used by specialty practices and medical centers in Massachusetts, Arizona, and California. RENE RUSSO came to Arsanis in 2015 as chief development officer, and was pro- moted to president and CEO within a year after spearheading the company’s clinical development plan. Since taking up that post, she’s helped get Arsanis’s CEO lead drug into Phase 2 trials, earned a fast-track designation from the FDA, and topped it off by raising a roughly $46 million round in April. JEFF ALBERS, a former executive at Algeta and Genzyme, took over Blueprint Medi- cines in July 2014 when it was privately held, had gone through two CEOs in a year, NANCY SIMONIAN is a true Boston life sciences veteran, starting out on the fac- and didn’t have a drug in clinical testing. He assembled the investor base for a ulty of before crossing over into industry and taking up $50 million crossover round, followed that up by forging partnerships with Alexion executive posts at Millennium Pharmaceuticals and Biogen. But she has earned a Pharmaceuticals and Roche, and led Blueprint to a $169 million IPO in April 2015. nomination for her work at Syros Pharmaceuticals. Simonian has led Syros since its The company has three drugs in clinical testing, and is currently worth more than founding in 2013 and helped the firm raise over $120 million in private cash, another three times its $18 IPO price. $58 million in an IPO, and advance it to the point where it now has two drugs in clinical testing. After leading and later selling Avila Therapeutics for $925 million to Celgene in 2012, KATRINE BOSLEY took over Editas Medicine in 2014 and led the company as it became the first ever publicly traded CRISPR-Cas9 drug developer. Soon after she Commitment to Diversity came aboard, Bosley helped raise $120 million, a round that laid the groundwork for a $94 million IPO in 2016. Editas could possibly be the first U.S. company to test Aiming to boost female board representation, BIOGEN launched an internal pro- CRISPR-Cas9 drugs in humans next year. gram in 2015 to prepare women for corporate governance. Last year, WOMEN IN BIO took the reins of what is now called Boardroom Ready and expanded the ED KAYE became Sarepta Therapeutics’s CEO in 2015, and guided the company program industry-wide. Nine of the 13 women in the 2015 class, and four from the through a volatile time to get the company’s first ever drug approved by the FDA. 2016 class, have been placed on corporate boards. Gaining approval for the Duchenne muscular dystrophy drug eteplirsen (Exondys 51) was critical to Sarepta’s survival and Kaye strengthened the company’s rela- Diversity helps Novartis discover and develop new drugs, says AMRI JOHNSON, tionship with the agency to pull it off. Now Sarepta has the money to develop other global head of diversity and inclusion at the Novartis Institutes for BioMedical Re- Duchenne treatments. Kaye stepped aside in June. search (NIBR). The company’s diversity initiatives include internal efforts, as well FINALISTS FINALISTS

as community outreach. More than 260 students have interned and conducted DENNIS AUSIELLO, after more than 16 years as chair of medicine at Massachusetts research at NIBR through its Students & Scholars program; many of those students General Hospital (MGH), founded the Center for Assessment Technology and Con- came from under-represented communities. tinuous Health in 2013. The center, a collaboration between MGH and MIT, brings software, technology, and medicine together to develop easy-to-use technolo- After finding little data about diversity at biotech companies, LIFTSTREAM CEO gies that can continuously monitor health. The aim is to use that health data to Karl Simpson decided to compile some. Surveys conducted by the life sciences improve early diagnostics and targeted treatments. recruitment firm produced hard figures and analysis that highlighted the gender imbalance on corporate boards and in senior management. Liftstream now uses DAVID BERRY can often be found at the interface of various fields: energy, synthetic its findings to shape content for its conferences, and in its recruitment work with life biology, agriculture, and more recently, the microbiome. As a general partner with science companies. Flagship Pioneering, he has co-founded and helped grow more than 20 compa- nies. One of his companies, Seres Therapeutics, recently started a phase 3 trial JOAN REEDE’s efforts to improve diversity at Harvard Medical School revolve testing its bacterial capsule on patients with recurrent Clostridium difficile infec- around a larger goal of connecting the university to the surrounding community. tion. Berry also co-founded Evelo Biosciences, which is working on specific strains As the medical school’s dean for diversity and community partnership, she has of microbes that modulate the immune system and other biological processes to created programs that provide support to STEM students at all levels of education, treat a range of diseases. address the recruitment and retention of medical students and faculty, and help prepare physicians to work in underserved areas. SANGEETA BHATIA has for years been mining new inventions at the intersection of biology, nanomaterials, microfabrication, and engineering. She has co-founded Software has historically been a male-dominated field butSOLABS has bucked the companies to commercialize her work, including “liver on a chip” technology, trend. The 50-employee company, which provides software to life science compa- which is now used to screen drugs for toxicity. She has combined nanotechnology nies, is 42 percent women. Though Solabs doesn’t have specific diversity programs, with medicine to develop cancer diagnostics. Bhatia, trained as an engineer and CEO Philippe Gaudreau says he has a personal goal of striving for equal represen- physician, has also moved into infectious disease, using artificial livers she devel- tation in the workforce. oped to study how malaria parasites infect the liver.

SUSAN WINDHAM-BANNISTER has made diversity a focus at each stop in her ca- EMULATE spun out of Harvard’s Wyss Institute in 2014, and has brought together mi- reer. A program started under her watch at the Massachusetts Life Sciences Center croengineering and cell biology to develop small, battery-sized chips that mimic continues to connect women and minorities to internship opportunities at local life how human organs function. Tens of thousands of human cells—from the brain, science companies. In her current consulting work, Windham-Bannister includes liver, or lung—are grown along tiny channels on the chip and recreate the condi- diversity in her company counsel. tions similar to those in the body. The FDA recently cut a deal with Emulate to con- duct toxicology tests for a variety of products, from food to dietary supplements. The hope is that one day the chips will become a standard part of preclinical Innovation at the Intersection drug development.

AKILI INTERACTIVE LABS aims to be the first company to receive approval from GINKGO BIOWORKS combines advanced manufacturing, synthetic biology, soft- the Food and Drug Administration to sell mobile video games as a medical de- ware, and robotics to custom-make yeast and other microbes that clients use to vice that can diagnose and treat a variety of cognitive disorders. The company produce everything from fragrances to food ingredients. The company uses soft- sits at the intersection of software and medicine. Its employees have back- ware to design a synthetic microbe’s genetic circuits, and with the help of robots grounds in video game development, the arts, data science, cognitive psychol- and other automation technologies, creates and tests it, and then rapidly pro- ogy, drug development, and more. Akili is testing its product on children with duces vast amounts of these organisms. Just this month, it announced that it is attention deficit hyperactivity disorder, and also hopes to target Parkinson’s dis- partnering with Bayer to create a new company that will make new crop-boosting ease and depression. microbes using Ginkgo’s technology. SPECIAL HONORS & TRIBUTE JUDGES

KATRINE BOSLEY is the Chief Executive Officer of Editas Medicine and has been Lifetime Achievement part of the industry for over 25 years. Through her career she has led innovative organizations (Avila Therapeutics–CEO; Adnexus Therapeutics–VP LITA NELSEN recently retired from her position as Director of the Technology Licens- Business Development) and worked to advance innovative products and tech- ing Office at MIT, where she had been since 1986. She now works as a consultant nologies (Tysabri (natalizumab), covalent drugs, ). in technology transfer and entrepreneurship in the U.S., Europe and Asia. She and her office became national leaders in university technology transfer, brokering GEORGE CHURCH is Professor at Harvard and MIT, co-author of 450 papers, 95 pat- many licensing deals between MIT and companies, and spinning out startups to ent publications and the book Regenesis. He developed methods used for the commercialize the university’s research in life sciences and other areas. Prior to first genome sequence (1994), genome recoding and million-fold DNA sequencing joining the MIT TLO, she spent 20 years in industry, primarily in the fields of mem- cost reductions since. He co-initiated the BRAIN Initiative (2011) and Genome Proj- brane separations, medical devices, and biotechnology. ects (1984, 2005) to provide and interpret the world’s only open-access personal precision medicine data. GEORGE WHITESIDES began his career as a professor at MIT, and is now the Wood- ford L. and Ann A. Flowers University Professor at . His current JAMES J. COLLINS is the Termeer Professor of Medical Engineering & Science and research interests include physical and organic chemistry, materials science, bio- Professor of Biological Engineering at MIT, as well as a Member of the Harvard-MIT physics, water, self-assembly, complexity and simplicity, origin of life, dissipative Health Sciences & Technology Faculty. He is also a Core Founding Faculty member systems, affordable diagnostics, and soft robotics. He is one of the country’s most of the Wyss Institute for Biologically Inspired Engineering at Harvard University, and cited chemists, and also co-founded the rare disease drugmaker Genzyme and an Institute Member of the Broad Institute of MIT and Harvard. His research group about a dozen other companies. works in synthetic biology and systems biology and his patented technologies have been licensed by over 25 biotech, pharma and medical devices compa- nies. Collins has also helped to launch a number of companies, including Sample6 In Memoriam Technologies, Synlogic and EnBiotix.

HENRI TERMEER was the CEO of Genzyme from 1983 until its acquisition by Sanofi DEBORAH DUNSIRE joined XTuit Pharmaceuticals in 2017 to focus on new thera- in 2011. He grew the company into a 10,000-employee powerhouse, transformed pies to address fibrosis and cancer through targeting the microenvironment. She it into the leader of rare disease drug development, and effectively launched the brings over 25 years of experience in developing and commercializing novel orphan drug field. After retiring from Genzyme, he began a new career creating, therapeutics across three continents. She is the former President and CEO at FO- investing in, and advising startups, as well as mentoring a new generation of CEOs RUM Pharmaceuticals, which focused on therapies for Alzheimer’s disease, other and biotech entrepreneurs. Termeer passed away in May at the age of 71. dementias and schizophrenia. She served as CEO and President of Millennium Pharmaceuticals from 2005 to 2013. Prior to Millennium, Dunsire spent 17 years at Tribute given by Alison Lawton Novartis, with 11 of those years at the helm of the Novartis Oncology business in North America. ALISON LAWTON is currently the chief operating officer of Aura Biosciences. From January 2013 to January 2014, Lawton served as COO of OvaScience. From 1991 to ROBERT LANGER is an Institute Professor at MIT. He has over 1,260 issued and pend- 2013, she worked in various positions of increasing responsibility at Genzyme and ing patents which have been licensed or sublicensed to over 350 companies. then Sanofi after it bought Genzyme in 2011. Lawton served as head of Genzyme Langer is one of only a few individuals elected to the National Academy of Medi- Biosurgery and prior to that oversaw global regulatory affairs and other groups. cine, the National Academy of Engineering, the National Academy of Sciences She sits on the board of directors of ProQR Therapeutics, Verastem, and Magenta and the National Academy of Inventors. Therapeutics and is on the Corporate Advisory Board for X4 Pharmaceuticals. TERRY MCGUIRE is founding partner of Polaris Partners and has 30 years of success- ful early stage investing experience in healthcare and technology companies. JUDGES ABOUT THE TROPHIES

As a venture capitalist, Terry has invested in nearly 50 companies which have ad- dressed the needs of more than 60 million patients.

ROB PEREZ is a biopharmaceutical executive with more than 25 years of experi- ence in the industry. He is currently the Founder and Chairman of Life Science Cares, and the Executive Chairman of Akili Interactive Labs. Previously, he was the Chief Executive Officer of Cubist Pharmaceuticals, a public pharmaceutical de- velopment company, when the company was acquired by Merck in January 2015. Prior to Cubist, he was a Vice President at Biogen.

VICKI L. SATO recently retired from Harvard Business School, after serving as Profes- sor of Management Practice since 2006. Prior to that, Sato was President of , and Vice President of Research at Biogen. Sato is currently a director of Bristol-Myers Squibb, BorgWarner Corporation, and Syros Pharmaceu- ticals, all publicly held companies. She was recently appointed co-chair of the Advisory Council of LifeSci NYC, a public service group that advises New York City on matters of life science competitiveness. She is also an advisor and director of privately held Denali Therapeutics and Vir Biotechnology.

PHILLIP A. SHARP is an Institute Professor at MIT and member of the Department of Biology and the Koch Institute for Integrative Cancer Research. He joined the Center for Cancer Research (now the Koch Institute) in 1974 and served as its direc- tor for six years, from 1985 to 1991, before taking over as head of the Department of Biology, a position he held for the next eight years. His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark discoveries earned Sharp the 1993 For Xconomy’s first awards, we wanted to make trophies that reflect the same spirit Nobel Prize in Physiology or Medicine. of innovation we’re honoring in our finalists and awardees. And since Boston is home to a burgeoning industry in 3D printing, we thought that would be the per- SUSAN WINDHAM-BANNISTER is the immediate past President and CEO of the Mas- fect technology for the job. sachusetts Life Sciences Center (MLSC), a state-funded investment organization charged with administering the $1 billion Life Sciences fund that was signed into We partnered with Somerville, MA-based Formlabs, which printed the trophies law in 2008. Under Windham-Bannister’s leadership, the MLSC invested nearly $700 with its new Form Cell system. Fun fact: Xconomy’s awards are the first products million of the fund and leveraged another $2.7 billion in matching investment capi- Formlabs has made for an outside group using Form Cell, which aims to automate tal. She currently serves as Managing Partner of Biomedical Innovation Advisors much of the printing process using a combination of robotics, software, and a bat- and as the President and CEO of Biomedical Growth Strategies. tery of the company’s Form 2 printers.

DAPHNE ZOHAR is the Founder and Chief Executive Officer of PureTech Health and The awards were designed by ZachZacks DesignWorks, a collaboration between a member of the Board. PureTech is developing new categories of medicine fo- Zach Kron, a senior product manager at Autodesk, and Xconomy’s co-founder, cused on the Brain-Gut-Immune (BIG) axis. PureTech has an advanced pipeline of Rebecca Zacks. They used Autodesk’s Dynamo Studio software—another product medicines, including two pivotal-stage and several-clinical stage programs tar- of the Boston innovation community—to create unique designs for each of the 11 geting serious diseases. awards categories. ABOUT XCONOMY UPCOMING EVENTS

XCONOMY is a unique news and events organization with outposts in key innova- Save $20 with the promotional code XconomyAwards tion clusters around the .

Through our online news network and our local forums and networking events, we are dedicated to providing the highest quality information about the business of technology—across information technology, life sciences, energy, and other high-tech fields. Xconomy is staffed by world-class journalists and supported by the Xconomists, 400+ of the country’s leading innovators.

You can reach these innovators through our array of integrated underwriting pro- grams, online awareness programs, and lead-generation products that include webinars, content syndication, and sponsored posts. You can also tap into our experts to help build your content.

To inquire about advertising on our website, sponsoring an Xconomy event, or any of our other products, please e-mail [email protected].

www.xconomy.com/subscribe

www.twitter.com/xconomy

www.facebook.com/xconomyinc

www.linkedin.com/company/xconomy PLATINUM SPONSORS

GOLD SPONSORS

SILVER SPONSORS